Journal of ISSN: 2377-4282 JNMR

Nanomedicine Research
Volume 7 Issue 2

Nanomedicine: a hope for mankind
Ting Ting Qiao,1 Jagadeesh Suriyaprakash2
1Shenyang Pharmaceutical University, China
2Shenyang National Laboratory for Materials Science, University of Chinese Academy of Sciences, China
Received: June 01, 2017 | Published: April 11, 2018

Correspondence: Jagadeesh Suriyaprakash, Shenyang National Laboratory for Materials Science, University of Chinese Academy of Sciences, Beijing, China, Email ;

Citation: Qiao TT, Suriyaprakash J. Nanomedicine: a hope for mankind. J Nanomed Res. 2018;7(2):86‒87. DOI: 10.15406/jnmr.2018.07.00182


Late 90s, mankind’s first ‘giant step’ has made in the medical science when the nanotechnology met the healthcare field. The new branch was emerged called “Nanomedicine” which can describe as follows: By engineering the nanodevices and designing the therapeutic drugs at the nanoscale level for the complete examining, control, construction, restore, protection, and enhancement of all human biological system.1 What makes the nanomedicine to flourish the future health care system?

The necessity

Conventional health care system is challenged by the three interlocking crises, i.e. (i) Cost, (ii) Demographic variation and (iii) Quality. Current statistics unfold that due to the poor quality of the present system, 15 % of the patient admitted to the hospitals suffered from the adverse event.10-20 % of all adverse events are caused by a medication error. The outcome of the conventional health care R&D labs is lesser than the cost invested. Usually, the patient responds to the therapy is always lower than 50 % in most chronic disease such as; Migraine, Rheumatoid arthritis, Osteoporosis, Alzheimer, Oncology, etc.2 Moreover, the present diagnostic system is based on the symptoms rather than prediction / prevention and lacking in early diagnosis/managing illness. To overcome these issues, development of the new technology is crucial. Hence, nanomedicine made the revolution in the healthcare by greatly improved directed therapies for treating cancer and cardiovascular disease using new nano-drug / gene delivery systems. The tiny implantable devices help to supervise the health precisely and nano-biosensor provides the data at the earliest stage of the disease.


Under the hood of nanomedicine, there are various robust machines (nanosensors,3,4 nanorobotics),5–8 analytical methods (quantum dot fluorescence,9,10 DNA proteomic arrays),11 new materials (biomimic, self-assembling materials),12 gene therapeutic materials (nanocapsules13) and new pharma system (nanoparticles labeled drugs, theranostics) has developed thus far. Currently, 44 nano-drug delivery and 15 nano-imaging / diagnosis products are commercially available. At the same time, regulation of these products is necessary before appearing to the public because of their toxicity.14 Today, it even remains difficult to challenge some of this postulation (safety vs. Efficiency). However, nanomedicine rewrite the history of the health care system by finding the cure and enhance the rate of patient response to the therapy in chronic diseases, such as HIV/AIDS,15 Tumor,16 Diabetics,13 and Malaria.17 In addition, one of the growing public health problems is ‘superbugs’ which is induced by the improper and excessive use of antibiotics has led to the evolution of antibiotic-resistant bacterial strains. Nanomedicine has started the work on this issue, already.


Common to all science is that discoveries always raise additional questions. Despite the fact that numerous research has done in a targeted drug delivery system yet the interaction of protein and nanosystem mechanism is mystified. A strong pipeline focused on various therapeutic areas is also expected to the growth of the nanomedicine in the academic as well as an industrial sector in the current era. The global nanomedicine market is scheduled for the amount of US$177 billion by 2019, which is highest in the general sector (food, electronics, etc).2 Undeniably, nanomedicine is the urgency of the future medicinal system; on the other hand, what we have achieved at present is barely scraping the surface in terms of nanotechnology role in the health care system, hence advancing this technology is necessary in the near future for better serving to the mankind.



Conflict of interest

The authors declare there is no conflict of interest.


  1. Zajtchuk R. New technologies in medicine: biotechnology and nanotechnology. Dis Mon. 1999;45:453–495.
  2. Evers P. Nanotechnology in medical application: The global market. BCC research Report; 2017.
  3. Kurbanoglu S, Ozkan SA. Electrochemical carbon based nanosensors: A promising tool in pharmaceutical and biomedical analysis. J Pharm Biomed Anal. 2018;147:439–457.
  4. Bala K, Suriyaprakash J, Singh P, et al. Copper and Cobalt nanoparticles embedded in naturally derived graphite electrode for sensing of neurotransmitter Epinephrine. New J Chem. 2018:1.
  5. Freitas RA. Pharmacytes: An Ideal Vehicle for Targeted Drug Delivery. J Nanosci Nanotechnol. 2006;6:2769–2775.
  6. Freitas RA. Exploratory Design in Medical Nanotechnology: A Mechanical Artificial Red Cell. Artificial Cells, Blood Substitutes, and Immobil Biotech. 1998;26:411–430.
  7. Conor AB. Drug delivery: DNA nanorobots-seek and destroy. Nature Reviews Drug Discovery. 2018;17:242.
  8. Zeeshan MA. Nanorobotic drug delivery: If i only had a heart. Mater Today. 2011;14:54.
  9. Mcleod E, Ozcan A. Nanoimaging enabled via self-assembly. Nano Today. 2014;9:560–573.
  10. Suriyaprakash J, Qiao TT. Exploiting the optical and luminescence characteristic of quantum dots for optical device fabrication. Appl Nanosci. 2018;1:0642.
  11. Hamdi M, Ferreira A. DNA nanorobotics. Microelectronics J. 2008;39:1051–1059.
  12. Thakur G. Designing Protein Self-Assembly for Smart Materials. J Nanomedicine Res. 2017;6:8–10.
  13. Zhi ZL, Khan F, Pickup JC. Multilayer nanoencapsulation: A nanomedicine technology for diabetes research and management. Diabetes Res Clin Pract. 2013;100:162–169.
  14. Mukhopdhyay S. Nanotoxicology: Assessment of Toxicological Properties of Nanomaterial. J Nanomedicine Res. 2017;6:9–10.
  15. Lisziewicz J, Toke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine. 2013;9:28–38.
  16. Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157.
  17. Bakshi R. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat Commun. 2018;9:1–8.
©2018 Qiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy